Lantern Pharma Enters into Strategic Collaboration with Deep Lens — Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer

~ Partnership designed to leverage artificial intelligence solutions to identify eligible patient subgroups faster and with more accuracy, complementing Lantern Pharma's RADR® A.I. platform ~ Collaboration to create an end-to-end A.I. drug development enabled pathway from drug rescue to patient recruitment

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here